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Abstract
Drug-induced liver injury (DILI) is a significant concern in drug development due to the poor concordance between
preclinical and clinical findings of liver toxicity. We hypothesized that the DILI types (hepatotoxic side effects) seen in the
clinic can be translated into the development of predictive in silico models for use in the drug discovery phase. We
identified 13 hepatotoxic side effects with high accuracy for classifying marketed drugs for their DILI potential. We then
developed in silico predictive models for each of these 13 side effects, which were further combined to construct a DILI
prediction system (DILIps). The DILIps yielded 60–70% prediction accuracy for three independent validation sets. To
enhance the confidence for identification of drugs that cause severe DILI in humans, the ‘‘Rule of Three’’ was developed in
DILIps by using a consensus strategy based on 13 models. This gave high positive predictive value (91%) when applied to an
external dataset containing 206 drugs from three independent literature datasets. Using the DILIps, we screened all the
drugs in DrugBank and investigated their DILI potential in terms of protein targets and therapeutic categories through
network modeling. We demonstrated that two therapeutic categories, anti-infectives for systemic use and musculoskeletal
system drugs, were enriched for DILI, which is consistent with current knowledge. We also identified protein targets and
pathways that are related to drugs that cause DILI by using pathway analysis and co-occurrence text mining. While
marketed drugs were the focus of this study, the DILIps has a potential as an evaluation tool to screen and prioritize new
drug candidates or chemicals, such as environmental chemicals, to avoid those that might cause liver toxicity. We expect
that the methodology can be also applied to other drug safety endpoints, such as renal or cardiovascular toxicity.
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Introduction
Drug-induced liver injury (DILI) poses a significant challenge to
medical and pharmaceutical professionals as well as regulatory
agencies. It is the leading cause of acute liver failure, which has a
high mortality rate (30%) as treatment is limited due to the
availability of livers for transplantation [1]. Although many
dangerous drugs are identified during animal testing thus
protecting humans from this damage, a consortium determined
that about half of the drugs that cause human hepatotoxicity
were not identified as having this potential in nonclinical
animal testing [2]. Many drugs have been withdrawn from the
market or have received restrictions and warnings due to DILI [3].
DILI information and guidance for pharmaceutical industries has
been released by regulatory agencies such as the U.S. Food and
Drug Administration (FDA) (http://www.fda.gov/downloads/
Drugs/GuidanceComplianceRegulatoryInformation/Guidances/
UCM174090.pdf), European Medicines Agency (EMA) (www.
ema.europa.eu/pdfs/human/swp/15011506en.pdf) and Health
Canada (http://www.hc-sc.gc.ca/dhp-mps/alt_formats/pdf/con-
sultation/drug-medic/draft_ebauche_hepatotox_guide_ld-eng.pdf),
highlighting both the significance and difficulties in DILI
research. In the FDA, the Critical Path Initiative identified
DILI as a key area of focus in a concerted effort to broaden the
agency’s knowledge for better evaluation tools and safety
biomarkers (http://www.fda.gov/ScienceResearch/SpecialTopics/
RegulatoryScience/ucm228131.htm).
Determining the potential for a drug candidate to cause DILI in
humans is a challenge. First, the standard pre-clinical animal
studies do not effectively predict DILI events in humans. In one
notorious example, five subjects in a phase 2 clinical trial
experienced fatal hepatotoxicity induced by fialuridine, an
investigational nucleoside analogue that showed no liver damage
in animal studies [4]. Out of 221 pharmaceuticals, the overall
concordance of liver toxicity in humans and experimental animals
is as low as 55%, which is in sharp contrast with the concordance
of other target organs such as the hematological (91%),
gastrointestinal (85%), and cardiovascular (80%) systems [2].
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predict post-marketing DILI events. The main reason for this is
the statistical power of the trials – the risk of severe DILI of an
idiosyncratic nature is very low per exposed subject, while clinical
trials are usually carried out with only several thousand patients
[5], rendering them significantly underpowered to predict rare
DILI events.
To enhance the predictability of DILI, novel approaches have
been explored by many researchers. Notable examples include (a)
development of new DILI biomarkers [6], (b) introduction of high-
content screening [7], (c) adoption of more sensitive animal models
[8,9,10], and (d) utilization of toxicogenomics [11]. Most of these
investigations are focused on developing biomarkers using either
animal or in vitro models for predicting DILI in humans. This still
would involve synthesis of the drug and elaborate testing. An in
silico approach could inform chemists at the earliest point in the
drug discovery pipeline and enable them to select the best
chemical structures.
We hypothesized that there exists a distinct set of liver side
effects that can be used to characterize the DILI risk of drugs in
humans. We identified 13 types of hepatotoxicity (hepatotoxic side
effects or HepSEs) from the organ levels of hepatobiliary disorders in
the Medical Dictionary for Regulatory Activities (MedDRA)
ontology (http://www.meddramsso.com/). We found that these
13 HepSEs can discriminate DILI drugs from non-DILI drugs
with high accuracy (,83%). Since the side effects are clinical
observations obtained either from clinical trials or from post-
marketing surveillance with limited utility in drug discovery, we
developed quantitative structure-activity relationship (QSAR)
models for each of the HepSEs. We then constructed a DILI
prediction system (DILIps) based on the 13 HepSE models with an
improved prediction strategy using a ‘‘Rule of Three’’ (RO3)
criterion (incriminated by 3 or more HepSE models). The systems
were evaluated in several external test sets with performance
surpassing most in silico models in the field. We screened the entire
drug list using the DILIps and evaluated the RO3 drugs in terms
of therapeutic use and drug targets.
Results
Identification and assessment of hepatotoxic side effects
(HepSEs)
Figure 1 is an overview of the approach taken. First, the
identification and assessment of HepSEs were performed. We used
the SIDER database [12] to identify drugs and associated side
effects. Out of 1450 side effects in the database, we selected only
those that were caused by more than 20 drugs (an arbitrary cut-
off). This yielded 473 side effects. The distribution of 888 drugs
over 473 side effects and vice verse were depicted in Supplemen-
tary Figure S1, indicating that over 90% drugs were associated
with at least 10 side effects. These side effects were then directly
mapped onto low level terms of MedDRA. The terms were linked
to the system organ classes (SOC) level according to the
hierarchical structure of MedDRA (Supplementary Table S1) in
order to determine the terms’ attributes at the organ level. Finally,
we considered side effects defined by the MedDRA ontology as
related to the hepatobilliary disorders SOC term as HepSEs, and
identified 13 HepSEs: bilirubinemia, cholecystitis, cholelithiasis, cirrhosis,
elevated liver function tests, hepatic failure, hepatic necrosis, hepatitis,
hepatomegaly, jaundice, liver disease, liver fatty, and liver function tests
abnormal.
We evaluated these 13 HepSEs for their ability to differentiate
drugs that do and do not cause DILI using the Liver Toxicity
Knowledge Base Benchmark Dataset (LTKB-BD) [13] and
PfizerData [14]. For both datasets, we used only the drugs that
they had in common with SIDER. There are several differences
between two datasets to call a drug as DILI or non-DILI (see
Materials and methods), including (1) LTKB-BD is based on the FDA-
approved drug labeling while PfizerData is according to the case
reports; (2) two datasets apply different criteria for DILI
assessment; and (3) drugs are grouped differently between two
datasets. To obtain an objective evaluation for 13 HepSEs, we
took the following actions to select DILI positive and negative
drugs from two datasets: (a) in LTKB-BD [13], Most-DILI-
Concern drugs were classified as positive while No-DILI-Concern
drugs were classified as negative; and (b) in PfizerData [14], drugs
with evidence in human toxicity were considered DILI positive
while drugs with no evidence in any species were considered DILI
negative. Defining a drug as causing DILI if it was positive in any
of the 13 HepSEs, this approach yielded 91% and 74% accuracy
for LTKB-BD and PfizerData, respectively.
It is important to note that the 26 MedDRA SOCs are not all
strictly related to human organs in a conventional sense. For
example, ‘‘investigations’’ and ‘‘general disorders and administra-
tion site conditions’’ are not organs (the complete list of MedDRA
SOC is available in Supplementary Table S1). Some side effects
with DILI indication are resided in a SOC other than the
hepatobilliary disorders. For example, the SOC of ‘‘investigations’’
include the ‘‘elevate liver enzyme’’ and ‘‘alkaline phosphatase
increased’’, both are conventional DILI indicators. Moreover,
some side effects in the SOC of ‘‘general disorders and
administration site conditions’’ could also be the manifestations
of DILI. Thus, we conducted a permutation test with the purposes
of confirming that the 13 HepSEs do in fact have significant
performance over the chance to distinguish DILI drugs from non-
DILI drugs. We randomly selected 3, 5,…, 21 side effects from the
473 side effect pool with each selection repeated 20,000 times. As
shown in Figure 2, the classification accuracy of the 13 HepSEs,
indicated by the red dot, was considerably higher than the average
accuracy for each of the sets of randomly selected side effects,
demonstrating that the observed classification accuracy for the 13
HepSEs was not due to chance.
Author Summary
Translational research involves utilization of clinical data to
address challenges in drug discovery and development.
The rationale behind this study is that the side effects
observed in clinical trial and post-marketing surveillance
can be translated into a screening system for use in drug
discovery. As a proof-of-concept study, we developed an
in silico system based on 13 hepatotoxic side effects to
predict drug-induced liver injury (DILI), which is one of the
most frequent causes of drug failure in clinical trial and
withdrawal from post-marketing application, and also one
of the most difficult clinical endpoints to predict from
preclinical studies. We first identified 13 types of liver
injury which yielded high prediction accuracy to distin-
guish drugs known to cause DILI from these don’t. To
effectively apply these 13 hepatotoxic side effects to the
drug discovery process for DILI, we developed in silico
models for each of these side effects solely based on
chemical structure data. Finally, we constructed a DILI
prediction system (DILIps) by combining these 13 in silico
models in a consensus fashion, which yielded .91%
positive predictive value for DILI in humans. The DILIps
methodology can be extended in applications for address-
ing other drug safety issues, such as renal and cardiovas-
cular toxicity.
Drug-Induced Liver Injury Prediction System
PLoS Computational Biology | www.ploscompbiol.org 2 December 2011 | Volume 7 | Issue 12 | e1002310Figure 1. Overview of the workflow of DILIps development and its evaluation.
doi:10.1371/journal.pcbi.1002310.g001
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PLoS Computational Biology | www.ploscompbiol.org 3 December 2011 | Volume 7 | Issue 12 | e1002310Figure 2. Box plot of classification accuracy with the number of selected side effects using a permutation test. (a) The test consisted of
128 drugs with a ratio of 69 DILI positives versus 59 DILI negatives in the LTKB-BD, and (b) 258 drugs with a ratio of 168 DILI positive drugs and 90 DILI
negative drugs in PfizerData. Given a randomly selected number of side effects, a drug showing positive in any of the side effects was considered as a
DILI positive drug. The process was repeated 20,000 times for each of the selected number of side effects. The red dot denotes the data based on the
13 HepSEs selected from the MedDRA hepatobilliary disorders category.
doi:10.1371/journal.pcbi.1002310.g002
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As illustrated in step 2 (Figure 1), QSAR models were developed
for each of the 13 HepSEs to enable their use in screening new
drug candidates computationally. The QSAR models developed
from the drugs related to each of these 13 HepSEs had high
prediction accuracy (.93%) in a leave-one-out cross-validation
(LOO-CV) process (Table 1).
Based on the 13 HepSE models, we further developed the
DILIps (step 3 of Figure 1, left box). Using the same classification
rule described above (i.e., drugs incriminated by any of the 13
HepSEs models are considered as DILI positives), we applied
DILIps to three external validation sets. The validation sets of
LTKB-BD and PfizerData contain drugs not used in developing
the 13 HepSE models. For the O’Brien et al. dataset [15], the
severe and moderate hepatotoxicity drugs were combined as DILI
positive drugs while the non-toxic drugs were defined as DILI
negative drugs (only the drugs not used by the 13 HepSE models
were included). As summarized in Table 2, the DILIps exhibited a
reasonable prediction performance for three external validation
sets with the prediction accuracy between 60–70%.
Development of the ‘‘Rule of Three’’ criterion in DILIps
Identifying the drugs of severe DILI potential with high
confidence has an important application since these drugs are
likely withdrawn from the market or restricted in use with black
box warning (BBW) due to the serious public health concern. We
assume that the number of models calling a drug causing DILI is
positively correlates with the drug’s severity for DILI and to the
extension of the confidence to make such a call. We generated a
union set based on the three validation datasets listed in Table 2.
We removed three drugs having an inconsistent DILI assignment
among three datasets (only three drugs were removed: moxisylyte,
carbidopa and terfenadine), i.e., positive in one dataset and
negative in another. This process resulted in 145 DILI positives
and 63 DILI negatives (see Supplementary Table S2). We used
this union set to assess how many HepSE models to be combined
likely identify high risk DILI drugs (i.e., withdrawal or BBW drugs)
with high positive predictive value (PPV).
Specifically, for each of the possible HepSE combination models
requiring a drug to be incriminated by N HepSE models (‘‘Rule of
N’’), we calculate PPV and the number of drugs retained by each
of the HepSE combination models. As depicted in Figure 3, the
PPV reaches a maximum of 91.3% when N=3. Additionally, the
percentage of high risk DILI drugs reached a local maximum at
N=3. Therefore, we established the RO3 criterion in the DILIps
for identifying drugs that might cause severe DILI with high
confidence (step 3 of Figure 1, right box). The number of drugs
meeting the RO3 is 23, dramatically decreased from 100 (RO1)
and 49 (RO2), which was expected when the optimization was
tilted toward increasing PPV. In order to identify the drugs of
severe DILI potential with high confidence, the trade-off was
accepted in the context of an application. Therefore, the RO3 was
selected to carry out further study.
DILI potential varies for different therapeutic categories
We applied the RO3 criterion to the drugs (small molecules
only) in DrugBank to investigate which therapeutic categories were
most likely associated with DILI (represented by the graph at the
Table 1. Performance of leave-one out cross-validation for the 13 HepSE models.
HepSE models # of drugs positive in HepSE Accuracy Sensitivity Specificity
bilirubinemia 88 0.96 0.76 0.99
cholecystitis 53 0.98 0.83 0.99
cholelithiasis 60 0.98 0.75 0.99
cirrhosis 27 0.99 0.89 0.99
elevated liver function tests 29 0.99 0.76 1.00
hepatic failure 132 0.95 0.82 0.97
hepatic necrosis 56 0.97 0.91 0.97
hepatitis 254 0.93 0.91 0.94
hepatomegaly 62 0.96 0.71 0.97
jaundice 274 0.93 0.89 0.95
liver disease 42 0.98 0.74 0.99
liver fatty 22 0.99 0.82 0.99
liver function tests abnormal 111 0.95 0.83 0.97
doi:10.1371/journal.pcbi.1002310.t001
Table 2. Performance of DILI prediction system (DILIps) on three literature datasets.
Datasets* The number of drugs for analysis (DILI positive drugs/DILI negative drugs) Accuracy Sensitivity Specificity
LTKB-BD 67/6 0.66 0.66 0.67
PfizerData 92/56 0.60 0.52 0.73
O’Brien et al. 25/15 0.70 0.56 0.93
*Only the drugs that did not overlap with the SIDER database were used.
doi:10.1371/journal.pcbi.1002310.t002
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across 14 therapeutic categories as defined by Anatomic
Therapeutic Class (ATC) (http://www.whocc.no/atcddd/) with
the RO3 positive drugs highlighted in red. The enrichment of the
RO3 drugs in each therapeutic category was determined by
Fisher’s exact test. We found that two therapeutic categories (i.e.,
anti-infective for systemic use and musculoskeletal system drugs)
were significantly associated with drugs that cause DILI (p-
value=5.00E-11 and 0.002, respectively). To confirm the findings,
we carried out the same analysis for drugs in the SIDER database
that met the RO3. As shown in Figure 4(b), the same two
therapeutic categories were also found to be significantly
associated with drugs that cause DILI (p-value=8.94E-8 and
2.36E-7, respectively). Both results demonstrated that care must be
taken when drugs are developed with existing targets in these two
categories.
The findings are consistent with real-world observations; for
example, non-steroidal anti-inflammatory drugs (NSAIDs, a
subcategory of anti-infectives for systemic use) are often associated
with DILI. A good example is didanosine (VidexH) which is an
antiviral drug used to treat human immunodeficiency virus (HIV)
infection. On Jan 29
th, 2010, the FDA notified healthcare
professionals and patients about a rare but serious complication
in the liver known as non-cirrhotic portal hypertension in patients
using the drug. Subsequently, a black box warning was added to
the drug label to warn doctors and consumers of this risk.
Didanosine can also cause lactic acidosis and severe hepatomegaly
with steatosis, and has resulted in several fatal cases (http://
dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=23496).
Associating the protein targets with DILI potential via
network analysis
It was important to determine if the drug target is related to the
drug’s likelihood of causing DILI. Accordingly, we investigated the
drugs that were RO3 positive from DrugBank in the target space
using network analysis as illustrated on the left side of Figure 1,
step 4. These drugs were associated with 134 human protein
targets. In the network analysis, we considered that two protein
targets are directly related (connected with an edge in network
analysis) if one or more drugs were associated with both targets.
As depicted in Figure 5, the network contains two large modules
(Modules #1 and #2) with several small modules. There are 72
targets in Module #1 associated with 125 RO3 positive drugs, and
23 targets in Module #2 associated with 8 drugs. We conducted
toxicity function and pathway analyses using Ingenuity Pathway
Analysis (IPA, http://www.ingenuity.com/) for both modules. In
each module, particularly Module #1, the biological functions
related to disease and disorder were investigated to assess if the
targets of the drugs meeting the RO3 have a relationship with
hepatic system diseases or disorders. As shown in Table 3, liver
injury and disease related functions enriched in Module #1 were
hepatic system disorder, jaundice, liver cancer, hepatocellular carcinoma, and
Figure 3. The evaluation of the ‘‘Rule of Three’’ (RO3). The predicted positive value, percentage of withdrawn or boxed warning (BW) drugs,
and the number of drugs meeting the ‘‘Rule of N’’ for different values of N in the combined HepSE model.
doi:10.1371/journal.pcbi.1002310.g003
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PLoS Computational Biology | www.ploscompbiol.org 6 December 2011 | Volume 7 | Issue 12 | e1002310Figure 4. The distribution of small molecular drugs in (a) DrugBank and (b) SIDER that satisfy the ‘‘Rule of Three’’ (RO3) at the first
level of Anatomical Therapeutic Chemical Classification System (ATC). The probability of the presence of DILI drugs is statistically significant
in two therapeutic categories (J and M).
doi:10.1371/journal.pcbi.1002310.g004
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hepatic system diseases branch of the top toxicity functions in IPA.
The other significant toxicity functions of Module #1 can be
found in Supplementary Table S3.
We also found that every drug in the two largest modules was
associated with more than three targets on average. Note that
drugs are prone to having multiple side effects if they interact with
multiple targets since different targets may invoke different side
Figure 5. Target network of corresponding drugs satisfying the ‘‘Rule of Three’’.
doi:10.1371/journal.pcbi.1002310.g005
Table 3. Summary of significant functions and pathways for module #1 identified in the network analysis of DILI targets using
IPA.
Functions Annotation p-Value Gene Name # Genes
hepatic system disorder 5.85E-25 ABCB1, ABCG2, ACSL4, ADRA1A, ADRA1B, ADRA1D, ALOX5, CASP3, CHRM1, CHRM2, CHRM3,
CHRM4, CHRM5, CHUK, DRD2, DRD5, HRH1, IKBKB, KIT, NR1I2, OPRM1, PDGFRA, PDGFRB,
PPARG, PTGS1, PTGS2, RXRA, SLC6A3, SLC6A4, TOP2A, VEGFA
31
jaundice 2.69E-15 CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, CHUK, HRH1, IKBKB 8
liver cancer 5.58E-11 ABCB1, CA2, CASP3, HTR3A, KIT, LCK, PDGFRA, PDGFRB, PTGS1, PTGS2, RARA, SLC6A3,
SLC6A4, SRC, TOP2A, VEGFA
16
hepatocellular carcinoma 7.76E-08 CA2, CASP3, KIT, PDGFRA, PDGFRB, PTGS1, PTGS2, RARA, TOP2A, VEGFA 10
hepatitis C 1.04E-07 CASP3, DRD2, DRD5, OPRM1, PPARG, SLC6A4 6
doi:10.1371/journal.pcbi.1002310.t003
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of 13 HepSEs and 134 targets identified by RO3 positive drugs.
We identified 45 proteins associated with eight HepSEs in a co-
occurrence analysis (Figure 6 and Supplementary Table S4). Most
of these targets are associated with hepatitis, while targets such as
PTGS2/COX-2 (prostaglandin-endoperoxide synthase 2) and
ABCD1 (ATP-binding cassette, sub-family, and member 1) are
related to multiple HepSEs.
Discussion
One application of translational science involves utilization of
clinical data to address challenges in drug discovery. The key
concept of this study is that the side effects observed in clinical
trials and post-marketing surveillance can be translated for use in
drug discovery. As a proof-of-concept study, we developed the
DILIps to address one of the most difficult clinical endpoints to
predict from preclinical studies, that is DILI. The DILIps contains
three distinct and sequential approaches. First, we identified 13
HepSEs based on the MedDRA ontology, which provided
excellent discrimination of a drug’s potential to cause DILI
(91% and 74% accuracy for LTKB-BD and PfizerData,
respectively). Secondly, HepSE-based QSAR models were devel-
oped by using all 888 drugs in SIDER, which were highly
predictive as compared to published models [14,18,19] and
offered a robust translation of clinical observation (i.e., side effects)
using in silico techniques to the drug discovery/preclinical testing
aspect of drug development. Next, we developed DILIps by
combining these 13 HepSE QSAR models, which yielded 60–70%
prediction accuracy for three independent validation sets. Lastly, a
RO3 criterion was implemented in DILIps, which had .91%
confidence for identification of drugs that might cause severe
DILI.
The DILIps is a modular system; each of its components can be
replaced by other methods or constructed using different variables.
For example, besides selecting 13 HepSEs from the hepatobiliary
disorders category in MedDRA, we also examined the effect of
including additional two DILI related terms from the investigation
SOC category, or selecting 14 DILI relevant terms as suggested by
an expert (Supplementary Table S5). Both yielded similar
performance compared to the 13 HepSE-based approach. Given
the fact that each MedDRA category is a stand-alone ontology and
other options did not yield exceptional performance, we choose
the terms under hepatobiliary disorders as representative types of DILI
in this study. For the second component of the DILIps, we
developed HepSE-based QSAR models because chemical struc-
ture data were readily available for the entire set of 888 drugs in
SIDER, providing a sufficiently large sample from which to build
the HepSE-based models. Other technologies, such as gene
expression microarrays, might be able to construct better HepSE
models. However, the data from these technologies was not
available for the complete set of SIDER drugs. With different
choices in components 1 and 2, the criterion in component 3 of
DILIps could be altered to optimize DILI classification using
different consensus approaches instead of RO3. Therefore, the
DILIps is subject to change and improvement when new data,
technology, and knowledge are available.
Development of predictive models for drugs that might cause
DILI in humans has been an active research field, with much of
the work being done using QSARs. However, the DILI labels used
in these studies are from different sources, some focused on case
reports and others developed using text mining. Furthermore, the
methods used to develop the models are also different. Thus, it is
difficult to compare these methods. For example, Greene et al. [14]
Figure 6. Text mining results to associate types of DILI
(columns) with protein targets (rows). The number of co-
occurrences (papers) between a target and a side effect type is
indicated in the cell. In each cell, the total number of reports as well as
the normalized value (shown in parenthesis) is provided. The
normalized value is the ratio of the number of co-occurrence reports
divided by the total number of reports for a protein target.
doi:10.1371/journal.pcbi.1002310.g006
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system, to predict a drug’s potential to cause DILI using the DILI
classification scheme developed by Pfizer. The system has 56%
overall accuracy with 73% specificity and 46% sensitivity.
Fourches et al. [18] applied text mining for DILI reported in
different species using MEDLINE abstracts, suggesting that the
concordance of liver effects is low (i.e., 39–44%) between different
species. They also developed QSAR models using a text mining
approach to define DILI classification with external prediction
accuracies ranging from 56 to 73%. Very recently, Ekins et al. [19]
developed a Bayesian model based on DILI endpoint from cellular
imaging predictions [7], which gave a concordance of 60%,
sensitivity of 56%, and specificity of 67%.
Development of DILI models for humans is always confronted
by two distinct but related challenges: (1) a comprehensive drug list
with DILI annotation is usually not available, and (2) there is no
authoritative assessment of whether a drug causes DILI or not. In
this study, we compiled three large datasets from our LTKB
project. We used only the drugs of the opposite extremes in DILI
classification (positive or negative in relationship to DILI) by
removing drugs with ambiguous call. The RO3 criterion of
DILIps reached .91% positive predictive value for a combined
drug list from these three literature datasets. We also applied
DILIps for the drugs with ambiguous call and the results are
available from Supplementary Table S6.
The translation of clinical observations to evaluation of drugs
earlier in the drug development pipeline is a goal of translational
medicine [20]. DILI is an endpoint influenced by several
important factors, and it is difficult to adequately predict with a
single model. The SIDER database has collected clinical
observation data (side effects) from drug labels and the scientific
literature, which allows the linkage of disease endpoints and
related symptom profiles. This, in turn, provides an opportunity to
combine drug information and patient information into a unified
prediction method, a focus of this study. The HepSEs provide a
new direction to predict DILI based on the consensus of multiple
clinical endpoints (side effects) using an in silico method.
Elucidation of therapeutic uses, drug targets, and pathways
related to DILI from a systematic perspective is of great use in
drug discovery and pharmacovigilance. By applying the RO3
criterion to the entire drug space defined by DrugBank, we
constructed a DILI landscape in terms of therapeutic and drug
target space. We do acknowledge that the findings from this excise
are dependent on the accuracy in annotation in DrugBank.
We identified two therapeutic categories (i.e., anti-infectives for
systemic use and musculoskeletal system drugs) in which the drugs
have a high risk for causing DILI. This is consistent with the
general understanding that, for example, NSAIDs (a subcategory
of anti-infectives for systemic use) are often associated with DILI
and have been subject to a broad range of studies looking into
drug-specific, therapeutic class-specific, and genetic-specific effects
[21]. Another possibility is that these drugs may have higher
exposure rates; they are widely used by many people over
prolonged periods, which may inadvertently increase the risk of
DILI. The RO3 positive criterion was able to identify most ‘‘bad
actors’’ among NSAIDs including celecoxib, diclofenac, diflunisal,
ibuprofen, leflunomide, and rofecoxib. Most of them are PTGS2
(COX-2) protein inhibitors. This gene is also involved in several
hepatic system pathways such as hepatic system disorder, liver cancer,
and hepatocellular carcinoma. COX (Cyclooxygenase) is an enzyme
that is responsible for formation of important biological mediators
called prostanoids. Pharmacological inhibition of COX can
provide relief from symptoms of inflammation and pain. However,
more and more reports indicated that the selective inhibition
profile of COXs can cause certain serious adverse drug reactions.
A classic example is rofecoxib (brand name VioxxH), which was
withdrawn in 2004 because of the risk of heart attack caused by
selective inhibition of COX-2. Rofecoxib was also associated with
DILI [22]. Another example is lumiracoxib, a selective COX-2
inhibitor developed for the symptomatic treatment of osteoarthritis
and acute pain. Concern over hepatotoxicity has contributed to
the withdrawal or non-approval of lumiracoxib in most major
drug markets worldwide [23]. Therefore, the study of the
relationship between drug target and DILI, such as COX
selectivity and DILI, may provide new insights into DILI at a
molecular level [24].
We also found that DILI drugs often involve multiple targets,
which is often associated with drugs applied in multiple
therapeutic categories [25]. Drugs interacting with multiple targets
are considered ‘‘dirty’’ since they have a potential to initiate
different adverse reactions. On the other hand, these drugs may
also hold the potential to be repositioned for use outside of their
original therapeutic indications. One such example is diclofenac,
which is used to relieve pain, tenderness, swelling and stiffness
caused by osteoarthritis, rheumatoid arthritis, and ankylosing
spondylitis. Diclofenac is labeled with four different ATC codes
(i.e., four different therapeutic uses) and associated with a number
of targets categorized by DrugBank, including prostaglandin G/H
synthase 1 and 2, the cytochrome P450 family (2C18/2E1/2C19/
1A2/2C8/2D6/2C9/3A4/1A1/2B6), the UDP-glucuronosyl-
transferase family (1–1,2B7), prostaglandin G/H synthase 1, etc.
Several case-control studies have been carried out to investigate
the role of polymorphisms in the gene encoding regions of the
aforementioned drug-metabolizing enzymes and transporters to
determine susceptibility to diclofenac-induced hepatotoxicity
[26,27,28,29,30]. Diclofenac has been withdrawn in several
countries due to liver injury and other adverse drug reactions,
including ulcers, bleeding, and ulcerations in the stomach and
intestinal linings [31]. Diclofenac induced liver injury causes a
number of side effect patterns, including cirrhosis, hepatic failure,
hepatic necrosis, hepatitis, jaundice, all of which were included in
our set of 13 HepSEs.
DILI is associated with two distinct but related parameters: drug
properties and patient susceptibility. Some drugs are more likely to
cause DILI, while some patients are more likely to show DILI.
The DILIps is primarily capable of addressing the former
challenge with an aim to enhance DILI identification in drug
discovery. Identifying genetic variations and their associated
protein products that contribute to DILI is another important
research area, but one that requires the costly and time-consuming
collection of samples from large numbers of affected individuals.
Study of the genetic risk factors to DILI or other conditions usually
involves the identification of genes associated with key disease
mechanisms and immunological reactions using genotyping
approaches. The network analysis conducted in this study
connected DILI drugs with pathways and targets and might
contribute to the identification of mechanisms that relate a
patient’s genetic predisposition and DILI. There are a small
number of genetic risk factors identified for DILI, most are
associated with a drug interaction with a specific HLA (human
leukocyte antigen system) polymorphism within the major
histocompatibility complex (MHC) such as lumiracoxib (HLA-
DRB1*15:01) [23], antituberculosis chemotherapy (HLA-
DQB1*02:01) [32], ticlopidine (HLA-A*33:03) [33], ximelagatran
(HLA-DRB1*07:01) [34], flucloxacillin (HLA-B*57:01) [21], and
amoxicillin-clavulanate (HLA-DRB1*15:01) [35]. Other genetic
risk factors such as those involving drug metabolizing enzymes are
exemplified by CYP2C8*4 (diclofenac), CYP2E1*1A (isoniazid),
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reported [36,37,38].
Drug safety is a key area of focus in the FDA. Modernizing
safety evaluation has been advocated by the FDA’s recent initiative
on advancing regulatory science with a proposal of incorporating
both in vitro and in silico methodologies in drug development and
safety assessment [39]. The DILIps follows the same philosophy
that underlies this new initiative at the FDA. It could be a
predictive system for FDA to utilize and reference when
hepatotoxicity issues arise during the various stages of the
regulatory review process. It could also serve as a proof-of-concept
approach of using predictive systems for drug safety to support the
FDA’s regulatory science. While the DILIps was developed for
DILI, its methodology can be applied equally well to address other
drug safety issues, such as renal and cardiovascular toxicity.
Materials and Methods
Preparation of datasets
SIDER database. SIDER is computer-readable database of
side effects which connects 888 drugs with 1450 different side
effect terms [12]. The side effects were extracted from drug labels
in either Structured Product Labeling (SPL) or Portable Document
Format (PDF) documents. The standardized Coding Symbols for a
Thesaurus of Adverse Reaction Terms (COSTART), a part of the
Unified Medical Language System (UMLS) Metatheasaurus, was
used as the basic lexicon of side effects. In this study, we
downloaded the entire database from http://sideeffects.embl.de/.
We then constructed a matrix with 888 drugs corresponding to
1450 side effects with supplementing the chemical structure data.
DrugBank. DrugBank (http://www.drugbank.ca) is a richly
annotated database of drugs and drug target information [40,41]. It
contains extensive information about nomenclature, chemistry,
structure, function, mode of action, pharmacology, pharma-
cokinetics, metabolism, and pharmaceutical properties of both
small molecule and large molecule (biotech) drugs. The updated
DrugBank 3.0 contains 6,800 drug entries including 1,400 FDA-
approved small molecule drugs, 132 FDA-approved biotech
(protein/peptide) drugs, 82 nutraceuticals and 5,200 experimental
drugs. In additional, more than 4,300 non-redundant protein (i.e.
drug target) sequences are linked to these drug entries [42].
In this study, information about 6620 small molecule drugs
(1,400 FDA drugs and 5,200 experimental drugs) was retrieved
including chemical structure, approval status, therapeutic catego-
ries and protein targets for use to generate the DILI landscape in
terms of therapeutic uses and drug targets.
LTKB benchmark dataset (LTKB-BD). As a part of the
LTKB project, a research team from the FDA’s National
Center for Toxicological Research has developed the LTKB-
BD dataset that contains 287 drugs with DILI annotation based
on the FDA-approved drug labels. The data are available
from http://www.fda.gov/ScienceResearch/BioinformaticsTools/
LiverToxicityKnowledgeBase/ucm226811.htm[13].Thedrugsare
classified into three categories: those of Most-DILI-Concern, Less-
DILI-Concern, and No-DILI-Concern. In this study, only those in
the Most-DILI-Concern (gemtuzumab was excluded since it is a
biotechnology product) and No-DILI-Concern categories were
used.Thedatasetwasdivided intotwosets.One setoverlappedwith
the SIDER database and contained 69 drugs of Most-DILI-
Concern and 59 No-DILI-Concern. This was used to evaluate the
performance of HepSEs. The rest of the LTKB-BD contained 67
drugs of Most-DILI-Concern and 6 of No-DILI-Concern that were
not in SIDER and were used to validate the DILIps performance
(Supplementary Table S6).
Pfizer hepatotoxicity dataset (PfizerData). Another
independent test set comes from part of the Derek for Windows
(DfW) system [14], which is a knowledge-based expert system
designed to assess the potential toxicity of a chemical from its
structure. A total of 626 compounds were classified into four
categories based on case reports, including evidence of human
hepatotoxicity (HH), no evidence of hepatotoxicity in any species
(NE), weak evidence (,10 case reports) of human hepatotoxicity
and evidence for animal hepatotoxicity but not tested in humans.
In this study, only HH and NE drugs were used, As a result, there
were 406 drugs remaining; 168 HH (positive) and 90 NE (negative)
overlapped with the SIDER database. The other 92 HH (positive)
and 56 NE (negative) that were not contained in the SIDER
database were selected as another independent test set
(Supplementary Table S6).
O’Brien et al. dataset. O’Brien et al. classified drugs into
four categories according to the severity of human hepatotoxicity
based on the frequency of an observed increase in ALT and other
evidence [15]. In this study, the categories of ‘‘Severely’’ and
‘‘Moderately’’ hepatotoxic drugs were considered DILI positive
drugs while non-toxic drugs were considered DILI negative, and
those that did not overlap with the SIDER database were
employed. The ratio of positive to negative drugs was 25/15
(Supplementary Table S6).
Data analysis method
Identification and assessment of Hepatotoxic Side Effects
(HepSEs). This section is shown as step 1 in Figure 1. There are
1450 different side effects listed in the SIDER database. We
identified 473 side effects for HepSE identification, with each side
effect associated with more than 20 drugs. We used MedDRA to
identify HepSEs. MedDRA is an ontology that provides a
controlled vocabulary describing adverse events. The 473 side
effect terms were mapped to the System Organ Class (SOC) level
of hepatobiliary disorders in MedDRA to extract the HepSEs
(Supplementary Table S1). The drugs in LTKB-BD which
overlapped with drugs in SIDER (128 total drugs) as well as
those in PfizerData which overlapped with drugs in SIDER (258
total drugs) were employed to assess the performance of HepSEs.
If a drug was associated with any HepSE as observed in the
SIDER database, it was considered as DILI positive. To determine
if the predictive performance of the 13 HepSE models was better
than would be expected by chance alone we randomly selected a
set of M side effects (M=3,5,…,21) and used these to predict DILI
potential. The selection process for each M was repeated 20,000
times, and the average performance of each M was compared to
the performance of the 13 HepSEs.
DILI prediction system (DILIps). Development of DILIps
consists of two steps (steps 2 and 3 of Figure 1). In step 2, all of the
drugs were transformed into well-established functional class
fingerprints (FCFP_6), structural fingerprint developed by Pipeline
Pilot 8.0 from SciTegic (http://accelrys.com/). It has been shown
in other studies that Bayesian models built using circular
fingerprints work very well in virtual screening tasks
[14,43,44,45,46,47]. Then, multiple-category naı ¨ve Bayesian
classifiers were trained for each of the selected HepSE
endpoints. In the training set, leave-one-out cross-validation
(LOO-CV) was employed to investigate the model performance.
For each model, a receiver operating characteristic plot (ROC
plot) was drawn to select the best Bayesian score (cut-off value) to
distinguish DILI drugs and non-DILI drugs.
In step 3, the independent test sets were submitted to the 13
HepSE models to calculate the Bayesian scores and give the
prediction results: For each HepSE endpoint, the predicted
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Bayesian score obtained in step 2. If PB-SCOREi . cut-off value,
the drug was considered positive for this endpoint and vice versa.
A drug was considered to have the potential to cause DILI if any of
the HepSE endpoints was called as positive (the left side of
Figure 1, step 3). In the right side of Figure 1 (step 3), consensus
prediction strategies were used to investigate the effectiveness of
combining results from multiple HepSEs into a single prediction.
A ‘‘Rule of N’’ strategy was evaluated, where 13 separate
consensus prediction strategies were examined with each predict-
ing a drug as causing DILI if N (N=1,2,…,13) HepSEs were
positive for that drug.
DILI landscape. Three sets of analysis were conducted,
which is summarized in step 4 of Figure 1. The right side of
Figure 1 is to assess the relationship of therapeutic use and DILI
potential of RO3 drugs. The Anatomical Therapeutic Chemical
(ATC) codes [48] for small molecule drugs which meet the ‘‘Rule
of Three’’ were extracted for this analysis.
The right side of Figure 1 is to assess the association of protein
targets and DILI potential of RO3 drugs. The protein targets
associated with small molecule drugs which meet the RO3
criterion were obtained from DrugBank 3.0. There are 4437
different protein targets from different organisms, and only the
human protein targets were selected. The protein target network
was built by considering two protein targets as connected if at least
one drug was associated with both targets. Two large modules
were identified using the SCAN algorithm, which is used to find
modules in the network [49]. The protein targets in these two large
modules were submitted to Ingenuity Pathway Analysis (IPA)
software (http://www.ingenuity.com/products/pathways_analysis.
html) for pathway analysis. In addition, a text mining with co-
occurrence analysis [50] was also employed to verify the protein
target and HepSE relationship from the network analysis. In this
analysis, the number of papers in PubMed that links a target with a
HepSE in a co-occurrence analysis was extracted. Since some
proteins are more extensively studied than others, the number of
papers associating the protein to the HepSE was normalized by
dividingthe numberofco-occurrencereportsbythe totalnumberof
reports of the related protein.
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Figure S1 The distribution of 888 drugs over 473 side
effects and vice versa.
(TIF)
Table S1 Information for the 473 side effects. Informa-
tion included: (1) the number of drugs involved; (2) system organ
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